- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00963885
A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection
November 1, 2016 updated by: Hoffmann-La Roche
A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infectio
This 2 part study will evaluate the efficacy and safety of 12 and 24 weeks treatment with RO5190591 (danoprevir) in combination with Pegasys and Copegus, compared to Pegasys and Copegus alone, in treatment-naive patients with chronic hepatitis C genotype 1 virus infection.In Part 1 of the study, patients will be randomized to receive either 1) RO5190591 300mg po every 8 hours, 2) RO5190591 600mg po every 12 hours, 3) RO5190591 900mg po every 12 hours or 4) placebo, in combination with standard doses of Pegasys and Copegus.
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive either 1) RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours or 2)placebo, in combination with standard doses of Pegasys and Copegus.
The anticipated time on study treatment is 24-48 weeks, and the target sample size is 100-500 individuals.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
229
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Kingswood, New South Wales, Australia
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
-
-
-
-
-
Wien, Austria, 1090
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
-
Edmonton, Alberta, Canada, T6G 2B7
-
Edmonton, Alberta, Canada, T5H 4B9
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
-
Vancouver, British Columbia, Canada, V5Z 1H2
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
-
Toronto, Ontario, Canada, M5G 1L7
-
-
-
-
-
Clichy, France, 92118
-
Marseille, France, 13285
-
Montpellier, France, 34295
-
Paris, France, 75651
-
-
-
-
-
Frankfurt Am Main, Germany, 60590
-
Hamburg, Germany, 20099
-
-
-
-
Campania
-
Napoli, Campania, Italy, 80131
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
-
-
California
-
Long Beach, California, United States, 90822
-
Los Angeles, California, United States, 90045
-
Sacramento, California, United States, 95817
-
San Diego, California, United States, 92123
-
San Diego, California, United States, 92154
-
-
Colorado
-
Aurora, Colorado, United States, 80045
-
-
Florida
-
Gainesville, Florida, United States, 32610-0214
-
Jacksonville, Florida, United States, 32256
-
Orlando, Florida, United States, 32809
-
-
Illinois
-
Lombard, Illinois, United States, 60148
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
-
Detroit, Michigan, United States, 48202-2689
-
-
New York
-
Manhasset, New York, United States, 11030
-
New York, New York, United States, 10029-6574
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
-
Chapel Hill, North Carolina, United States, 27599-7584
-
-
Oregon
-
Medford, Oregon, United States, 97504
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604-3200
-
-
Texas
-
San Antonio, Texas, United States, 78215
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
-
-
Washington
-
Vancouver, Washington, United States, 98664
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53210
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult patients, >=18 years of age;
- chronic hepatitis C, genotype 1;
- treatment-naive.
Exclusion Criteria:
- liver cirrhosis and other forms of liver disease;
- HIV infection;
- hepatocellular cancer;
- cardiac disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Part 1: Placebo
Placebo in combination with standard doses of Pegasys and Copegus.
|
1000 or 1200mg po daily for 24 or 48 weeks
180micrograms sc weekly for 24 or 48 weeks
po for 12 weeks
po for 24 weeks
|
Experimental: Part 1: RO5190591 300mg po
RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
|
1000 or 1200mg po daily for 24 or 48 weeks
180micrograms sc weekly for 24 or 48 weeks
300mg po q8h for 12 weeks
600mg po q12h for 12 weeks
900mg po q12h for 12 weeks
300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
|
Experimental: Part 1: RO5190591 600mg po
RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
|
1000 or 1200mg po daily for 24 or 48 weeks
180micrograms sc weekly for 24 or 48 weeks
300mg po q8h for 12 weeks
600mg po q12h for 12 weeks
900mg po q12h for 12 weeks
300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
|
Experimental: Part 1: RO5190591 900mg po
RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
|
1000 or 1200mg po daily for 24 or 48 weeks
180micrograms sc weekly for 24 or 48 weeks
300mg po q8h for 12 weeks
600mg po q12h for 12 weeks
900mg po q12h for 12 weeks
300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
|
Placebo Comparator: Part 2: Placebo
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
|
1000 or 1200mg po daily for 24 or 48 weeks
180micrograms sc weekly for 24 or 48 weeks
po for 12 weeks
po for 24 weeks
|
Experimental: Part 2: RO5190591 300mg po
If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
|
1000 or 1200mg po daily for 24 or 48 weeks
180micrograms sc weekly for 24 or 48 weeks
300mg po q8h for 12 weeks
600mg po q12h for 12 weeks
900mg po q12h for 12 weeks
300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sustained virological response
Time Frame: 24 weeks after end of treatment
|
24 weeks after end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Virological response over time
Time Frame: At 2- to 6-weekly intervals throughout study; at end of treatment; 12 weeks post-treatment
|
At 2- to 6-weekly intervals throughout study; at end of treatment; 12 weeks post-treatment
|
Adverse events; laboratory parameters
Time Frame: Throughout study, laboratory parameters every 2 to 6 weeks
|
Throughout study, laboratory parameters every 2 to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
August 18, 2009
First Submitted That Met QC Criteria
August 21, 2009
First Posted (Estimate)
August 24, 2009
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Anti-Infective Agents
- Antiviral Agents
- Anti-Bacterial Agents
- Peginterferon alfa-2a
- Lactams
Other Study ID Numbers
- NV21075
- 2009-009608-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C, Chronic
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on Copegus
-
Baqiyatallah Medical Sciences UniversityShahid Beheshti University of Medical Sciences; Guilan University of Medical... and other collaboratorsCompletedHemophilia | Hepatitis CIran, Islamic Republic of
-
Hoffmann-La RocheCompletedHepatitis C, ChronicUnited States, Puerto Rico
-
Hoffmann-La RocheCompleted
-
University Health Network, TorontoUnknownHepatitis B | Hepatitis CCanada
-
University Hospital, BonnCompletedHIV Infections | Hepatitis CGermany
-
Karolinska InstitutetThe Swedish Research Council; Hoffmann-La RocheCompletedChronic Hepatitis C | Human Immunodeficiency VirusSweden
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedHepatitis C, ChronicUnited States, Puerto Rico
-
Baqiyatallah Medical Sciences UniversityGuilan University of Medical Sciences; Baqiyatallah Research Center for Gastroenterology... and other collaboratorsCompletedHepatitis C | ThalassemiaIran, Islamic Republic of
-
Hoffmann-La RocheCompletedHealthy VolunteerUnited States